



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent
Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Extracorporeal Membrane Oxygenation

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 726

BCBSA Reference Number: 8.01.60 (For Plan internal use only)

NCD/LCD: N/A

Related Policies

Inhaled Nitric Oxide as a Treatment of Hypoxic Respiratory Failure in Neonates, #[100](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

ECMO for newborn and children up to 18 years of age may be [MEDICALLY NECESSARY](#).

The use of extracorporeal membrane oxygenation (ECMO) in adults may be considered [MEDICALLY NECESSARY](#) for the management of adults with acute respiratory failure when all of the following criteria are met:

- Respiratory failure is due to a potentially reversible etiology AND
- Respiratory failure is severe, as determined by one of the following:
 - A standardized severity instrument such as the Murray score*;
 - OR
 - One of the criteria for respiratory failure severity**AND
- None of the following contraindications are present:
 - High ventilator pressure (peak inspiratory pressure >30 cm H₂O) or high FIO₂ (>80%) ventilation for more than 168 hours;
 - Signs of intracranial bleeding;
 - Multisystem organ failure;
 - Prior (ie, before onset of need for ECMO) diagnosis of a terminal condition with expected survival <6 months;
 - A do-not-resuscitate (DNR) directive;
 - Cardiac decompensation in a patient already declined for ventricular assist device (VAD) or transplant;
 - KNOWN neurologic devastation without potential to recover meaningful function;
 - Determination of care futility***.

***Murray Score**

One commonly used system for classifying the severity of respiratory failure is the Murray scoring system, which was developed for use in ARDS but has been applied to other indications. This score includes 4 subscales, each of which is scored from 0 to 4. The final score is obtained by dividing the collective score by the number of subscales used. A score of 0 indicates no lung injury; a score of 1 to 2.5 indicates mild or moderate lung injury; and a score of 2.5 indicates severe lung injury, eg, ARDS. Table 2 shows the components of the Murray scoring system.

Table 2: Murray Lung Injury Score

Subscale	Criteria	Score
Chest x-ray score	No alveolar consolidation	0
	Alveolar consolidation confined to 1 quadrant	1
	Alveolar consolidation confined to 2 quadrants	2
	Alveolar consolidation confined to 3 quadrants	3
	Alveolar consolidation in all 4 quadrants	4
Hypoxemia score	PaO ₂ /FIO ₂ >300	0
	PaO ₂ /FIO ₂ 225-299	1
	PaO ₂ /FIO ₂ 175-224	2
	PaO ₂ /FIO ₂ 100-174	3
	PaO ₂ /FIO ₂ ≤100	4
PEEP score (when ventilated)	PEEP ≤ 5 cm H ₂ O	0
	PEEP 6-8 cm H ₂ O	1
	PEEP 9-11 cm H ₂ O	2
	PEEP 12-14 cm H ₂ O	3
	PEEP ≥15 cm H ₂ O	4
Respiratory system compliance score (when available)	Compliance >80 mL/cm H ₂ O	0
	Compliance 60-79 mL/cm H ₂ O	1
	Compliance 40-59 mL/cm H ₂ O	2
	Compliance 20-39 mL/cm H ₂ O	3
	Compliance ≤19 mL/cm H ₂ O	4

CPAP: continuous positive airway pressure; FIO₂: fraction of inspired oxygen; PaO₂: partial pressure of oxygen in arterial blood; PEEP: peak end expiratory pressure.

**** Alternative Respiratory Failure Severity Criteria**

Respiratory failure is considered severe if the patient meets one or more of the following criteria:

- Uncompensated hypercapnia with a pH less than 7.2; **or**
- PaO₂/FIO₂ of <100 mm Hg on fraction of inspired oxygen (FIO₂) >90%; **or**
- Inability to maintain airway plateau pressure (Pplat) <30 cm H₂O despite a tidal volume of 4 to 6 mL/kg ideal body weight (IBW); **or**
- Oxygenation Index >30: Oxygenation Index = FIO₂ × 100 × MAP/PaO₂ mm Hg. [FIO₂ x 100 = FIO₂ as percentage; MAP = mean airway pressure in cm H₂O; PaO₂=partial pressure of oxygen in arterial blood]; **or**
- CO₂ retention despite high Pplat (>30 cm H₂O).

***** Assessment of ECMO Futility**

Patients undergoing ECMO treatment should be periodically reassessed for clinical improvement. ECMO should not be continued indefinitely if the following criteria are met:

- Neurologic devastation as defined by the following:
 - Consensus from 2 attending physicians that there is no likelihood of an outcome better than “persistent vegetative state” at 6 month, **AND**
 - At least one of the attending physicians is an expert in neurologic disease and/or intensive care medicine, **AND**
 - Determination made following studies including CT, EEG and exam.

OR

- Inability to provide aerobic metabolism, defined by the following:
 - Refractory hypotension and/or hypoxemia, **OR**
 - Evidence of profound tissue ischemia based on creatine phosphokinase (CPK) or lactate levels, lactate-to-pyruvate ratio, or near-infrared spectroscopy (NIRS)
- OR**
- Presumed end-stage cardiac or lung failure without “exit” plan (ie, declined for assist device and/or transplantation).

The use of ECMO in adults may be considered **MEDICALLY NECESSARY** as a bridge to heart, lung, or combined heart-lung transplantation for the management of adults with respiratory, cardiac, or combined cardiorespiratory failure refractory to optimal conventional therapy.

The use of ECMO in adult patients is considered **INVESTIGATIONAL** when the above criteria are not met, including but not limited to acute and refractory cardiogenic shock and as an adjunct to cardiopulmonary resuscitation.

NOTE: Extracorporeal membrane oxygenation (ECMO) is considered investigational for most cases of cardiogenic shock. However, in individual clinical situations, ECMO may be considered beneficial/lifesaving for relatively short-term support (ie, days) for cardiogenic shock refractory to standard therapy in specific situations when shock is thought to be due to a potentially reversible condition, such as ST elevation acute myocardial infarction, acute myocarditis, peripartum cardiomyopathy, or acute rejection in a heart transplant, AND when there is reasonable expectation for recovery.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This procedure is performed in the inpatient setting.
Commercial PPO and Indemnity	This procedure is performed in the inpatient setting.
Medicare HMO BlueSM	This procedure is performed in the inpatient setting.
Medicare PPO BlueSM	This procedure is performed in the inpatient setting.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
33946	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; initiation, veno-venous
33947	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; initiation, veno-arterial
33948	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; daily management, each day, veno-venous
33949	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; daily management, each day, veno-arterial
33951	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of peripheral (arterial and/or venous) cannula(e), percutaneous, birth through 5 years of age (includes fluoroscopic guidance, when performed)
33952	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of peripheral (arterial and/or venous) cannula(e), percutaneous, 6 years and older (includes fluoroscopic guidance, when performed)
33953	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of peripheral (arterial and/or venous) cannula(e), open, birth through 5 years of age
33954	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of peripheral (arterial and/or venous) cannula(e), open, 6 years and older
33955	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of central cannula(e) by sternotomy or thoracotomy, birth through 5 years of age
33956	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of central cannula(e) by sternotomy or thoracotomy, 6 years and older
33957	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition peripheral (arterial and/or venous) cannula(e), percutaneous, birth through 5 years of age (includes fluoroscopic guidance, when performed)
33958	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition peripheral (arterial and/or venous) cannula(e), percutaneous, 6 years and older (includes fluoroscopic guidance, when performed)
33959	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition peripheral (arterial and/or venous) cannula(e), open, birth through 5 years of age (includes fluoroscopic guidance, when performed)
33962	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition peripheral (arterial and/or venous) cannula(e), open, 6 years and older (includes fluoroscopic guidance, when performed)
33963	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition of central cannula(e) by sternotomy or thoracotomy, birth through 5 years of age (includes fluoroscopic guidance, when performed)
33964	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition central cannula(e) by sternotomy or thoracotomy, 6 years and older (includes fluoroscopic guidance, when performed)
33965	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of peripheral (arterial and/or venous) cannula(e), percutaneous, birth through 5 years of age
33966	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of peripheral (arterial and/or venous) cannula(e), percutaneous, 6 years and older

33969	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of peripheral (arterial and/or venous) cannula(e), open, birth through 5 years of age
33984	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of peripheral (arterial and/or venous) cannula(e), open, 6 years and older
33985	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of central cannula(e) by sternotomy or thoracotomy, birth through 5 years of age
33986	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of central cannula(e) by sternotomy or thoracotomy, 6 years and older
33987	Arterial exposure with creation of graft conduit (eg, chimney graft) to facilitate arterial perfusion for ECMO/ECLS (List separately in addition to code for primary procedure)
33988	Insertion of left heart vent by thoracic incision (eg, sternotomy, thoracotomy) for ECMO/ECLS
33989	Removal of left heart vent by thoracic incision (eg, sternotomy, thoracotomy) for ECMO/ECLS

ICD-10 Procedure Codes

ICD-10-PCS-procedure codes:	Code Description
5A1522F	Extracorporeal Oxygenation, Membrane, Central
5A1522G	Extracorporeal Oxygenation, Membrane, Peripheral Veno-arterial
5A1522H	Extracorporeal Oxygenation, Membrane, Peripheral Veno-venous

Description

Extracorporeal Membrane Oxygenation

Extracorporeal membrane oxygenation (ECMO) provides extracorporeal circulation and physiologic gas exchange for temporary cardiorespiratory support in cases of severe respiratory and cardiorespiratory failure. Available ECMO devices use an extracorporeal circuit, combining a pump and a membrane oxygenator, to undertake oxygenation of and removal of carbon dioxide from the blood.

Developed in the 1970s and widely used, ECMO has proven effective in pediatric patients, particularly neonates suffering with respiratory and cardiopulmonary failure.¹ Initially, ECMO was thought to have little to no clinical value as an intervention for cardiorespiratory conditions such as severe acute respiratory distress syndrome (ARDS) in adults. Early trials correlated its use with higher complication rates due to the anticoagulation required for the ECMO circuit.² In addition, Zapol et al (1979) published a randomized controlled trial of ECMO in adults; the results indicated that both the intervention and control group had a 90% mortality rate, representing a 0% survival benefit for patients treated with ECMO.³

With improvements in ECMO circuit technology and methods of supportive care, interest in the use of ECMO in adults has renewed. For example, during the 2009-2010 H1N1 influenza pandemic, the occurrence of influenza-related ARDS in relatively young healthy people prompted an interest in ECMO for adults.

In general, ECMO has been used in clinical situations of respiratory or cardiac failure, or both. In these situations, when death is imminent unless medical interventions immediately reverse the underlying disease process, physiologic functions can be supported until normal reparative processes or treatment can occur (eg, resolution of ARDS, treatment of infection), or other life-saving interventions can be delivered (eg, provision of a lung transplant).

Disease-Specific Indications for Extracorporeal Membrane Oxygenation

Venoarterial (VA) and venovenous (VV) ECMO have been investigated for a wide range of adult conditions that can lead to respiratory or cardiorespiratory failure, some of which overlap clinical categories (eg, H1N1 influenza infection leading to ARDS and cardiovascular collapse), which makes categorization difficult. However, in general, indications for ECMO can be categorized as follows: (1) acute respiratory failure due to potentially reversible causes; (2) bridge to lung transplant; (3) acute-onset cardiogenic or obstructive shock; and (4) ECMO-assisted cardiopulmonary resuscitation.

Acute respiratory failure refers to the failure of either oxygenation, removal of carbon dioxide, or both, and may be due to a wide range of causes. The definition of ARDS has been established by consensus in the Berlin definition, which includes criteria for the timing of symptoms, imaging findings, exclusion of other causes, and degree of oxygenation.² In ARDS cases, ECMO is most often used as a bridge to recovery. Specific potentially reversible or treatable indications for ECMO may include ARDS, acute pneumonia, and various pulmonary disorders.

Lung transplant is used to manage chronic respiratory failure, most frequently in the setting of advanced chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, emphysema due to α 1-antitrypsin deficiency, and idiopathic pulmonary arterial hypertension. In the end stages of these diseases, patients may require additional respiratory support while awaiting an appropriate donor. Also, patients who have had a transplant may require retransplantation due to graft dysfunction of the primary transplant.

Acute-onset cardiogenic or obstructive shock is due to cardiac pump failure or vascular obstruction refractory to inotropes and/or other mechanical circulatory support. Examples include postcardiotomy syndrome (ie, failure to wean from bypass), acute coronary syndrome, myocarditis, cardiomyopathy, massive pulmonary embolism, and prolonged arrhythmias.

Extracorporeal membrane oxygenation-assisted cardiopulmonary resuscitation can be used as an adjunct to cardiopulmonary resuscitation in patients who do not respond to initial resuscitation measures.

Technology Description

The basic components of ECMO include a pump, an oxygenator, sometimes referred to as a "membrane lung," and some form of vascular access. Based on the vascular access type, ECMO can be described as VV or VA. Venoarterial ECMO has the potential to provide cardiac and ventilatory support.

Venovenous Extracorporeal Membrane Oxygenation

Technique

In VV ECMO, the ECMO oxygenator is in series with the native lungs, and the ECMO circuit provides respiratory support. Venous blood is withdrawn through a large-bore intravenous line, oxygen is added, and CO₂ removed, and oxygenated blood is returned to the venous circulation near the right atrium. Venous access for VV ECMO can be configured through 2 single lumen catheters (typically in the right internal jugular and femoral veins), or through 1 dual-lumen catheter in the right internal jugular vein. In the femorojugular approach, a single large multiperforated drainage cannula is inserted in the femoral vein and advanced to the cavo-atrial junction, and the return cannula is inserted into the superior vena cava via the right internal jugular vein. In the dual-lumen catheter approach, a single bicaval cannula is inserted via the right jugular vein and positioned to allow drainage from the inferior vena cava and superior vena cava and return via the right atrium.

Indications

Venovenous ECMO provides only respiratory support and therefore is used for conditions in which there is a progressive loss in the ability to provide adequate gas exchange due to abnormalities in the lung parenchyma, airways, or chest wall. Right ventricular dysfunction due to pulmonary hypertension secondary to parenchymal lung disease can sometimes be effectively treated by VV ECMO. However, acute or chronic obstruction of the pulmonary vasculature (eg, saddle pulmonary embolism) might require

VA ECMO, as well as cases in which right ventricular dysfunction due to pulmonary hypertension caused by severe parenchymal lung disease is severe enough. In adults, VV ECMO is generally used when all other reasonable avenues of respiratory support have been exhausted, including mechanical ventilation with lung protective strategies, pharmacologic therapy, and prone positioning.

Venoarterial Extracorporeal Membrane Oxygenation

Technique

In VA ECMO, the ECMO oxygenator operates in parallel with the native lungs, and the ECMO circuit provides both cardiac and respiratory support. In VA ECMO, venous blood is withdrawn, oxygen is added, and co2 removed similar to VV ECMO, but blood is returned to the arterial circulation. Cannulation for VA ECMO can be done peripherally, with the withdrawal of blood from a cannula in the femoral or internal jugular vein and the return of blood through a cannula in the femoral or subclavian artery. Alternatively, it can be done centrally, with the withdrawal of blood directly from a cannula in the right atrium and return of blood through a cannula in the aorta. Venoarterial ECMO typically requires a high blood flow extracorporeal circuit.

Indications

Venoarterial ECMO provides both cardiac and respiratory support. Thus, it is used in situations of significant cardiac dysfunction refractory to other therapies, when significant respiratory involvement is suspected or demonstrated, such as treatment-resistant cardiogenic shock, pulmonary embolism, or primary parenchymal lung disease severe enough to compromise right heart function. Echocardiography should be used before ECMO is considered or started to identify severe left ventricular dysfunction that might necessitate the use of VA ECMO. The use of peripheral VA ECMO in the presence of adequate cardiac function may cause severe hypoxia in the upper part of the body (brain and heart) in the setting of a severe pulmonary shunt.⁴

Extracorporeal Carbon Dioxide Removal

Also, to complete ECMO systems, there are ventilation support devices that provide oxygenation and remove co2 without the use of a pump system or interventional lung assist devices (eg, iLA® Membrane Ventilator; Novalung GmbH). At present, none of these systems have U.S. Food and Drug Administration (FDA) approval for use in the U.S. These technologies are not the focus of this evidence review but are briefly described because there is overlap in patient populations treated with extracorporeal carbon dioxide removal and those treated with ECMO, and some studies have reported on both technologies.

Unlike VA and VV ECMO, which use large-bore catheters and generally high flow through the ECMO circuits, other systems use pumpless systems to remove co2. These pumpless devices achieve extracorporeal carbon dioxide removal via a thin double-lumen central venous catheter and relatively low extracorporeal blood flow. They have been investigated as a means to allow low tidal volume ventilator strategies, which may have benefit in ARDS and other conditions where lung compliance is affected. Although ECMO systems can affect co2 removal, dedicated extracorporeal carbon dioxide systems are differentiated by simpler mechanics and by no need for dedicated staff.⁵

Medical Management During Extracorporeal Membrane Oxygenation

During ECMO, patients require supportive care and treatment for their underlying medical condition, including ventilator management, fluid management, systemic anticoagulation to prevent circuit clotting, nutritional management, and appropriate antimicrobials. Maintenance of the ECMO circuit requires frequent monitoring by medical and nursing staff and evaluation at least once per 24 hours by a perfusion expert.

Extracorporeal membrane oxygenation may be associated with significant complications, which can be related to the vascular access needed for systemic anticoagulation, including hemorrhage, limb ischemia, compartment syndrome, cannula thrombosis, and limb amputation. Patients are also at risk of progression of their underlying disease.

Summary

Extracorporeal membrane oxygenation (ECMO) provides extracorporeal circulation and physiologic gas exchange for temporary cardiorespiratory support in cases of severe respiratory and cardiorespiratory failure. Generally, ECMO has been used in clinical situations in which there is respiratory or cardiac failure, or both, in which death would be imminent unless medical interventions can immediately reverse the underlying disease process, or physiologic functions can be supported long enough that normal reparative processes or treatment can occur (eg, resolution of acute respiratory distress syndrome, treatment of infection), or other life-saving intervention can be delivered (eg, provision of a lung transplant). Potential indications for ECMO in the adult population include acute, potentially reversible respiratory failure due to a variety of causes; as a bridge to lung transplant; in potentially reversible cardiogenic shock; and as an adjunct to cardiopulmonary resuscitation (ECMO-assisted cardiopulmonary resuscitation [ECPR]).

For individuals who are adults with acute respiratory failure who receive extracorporeal membrane oxygenation (ECMO), the evidence includes randomized controlled trials (RCTs), systematic reviews, and nonrandomized comparative studies. Relevant outcomes are overall survival (OS), change in disease status, morbid events, and treatment-related mortality and morbidity. The most direct evidence on the efficacy of ECMO in adult respiratory failure comes from the CESAR trial. Although this trial had limitations, including nonstandardized management of the control group and unequal intensity of treatment between treatment and control groups, for the trial's primary outcome (disability-free survival at 6 months), there was a large effect size, with an absolute risk reduction in mortality of 16.25%. Recent nonrandomized comparative studies have generally reported improvements in outcomes with ECMO. The available evidence supports the conclusion that outcomes are improved for adults with acute respiratory failure, particularly those who meet the patient selection criteria outlined in the CESAR trial. However, questions remain about the generalizability of findings to other patient populations, and additional clinical trials in more specific patient populations are needed. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are adult lung transplant candidates who receive ECMO as a bridge to lung transplantation, the evidence includes 2 large nonrandomized comparator studies and small case series. Relevant outcomes are OS, change in disease status, morbid events, and treatment-related mortality and morbidity. One of the large comparator studies found that patients receiving ECMO had 3-year survival rates similar to patients receiving no support and significantly better survival rates than patients receiving invasive mechanical support. Small case series generally reported high positive rates of success for ECMO as a bridge to transplant. Given the lack of other treatment options for this population and the suggestive clinical evidence, ECMO may be an appropriate therapy for this patient population. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are adults with acute cardiac failure who receive ECMO, the evidence includes meta-analyses, observational studies, and case series. Relevant outcomes are OS, change in disease status, morbid events, and treatment-related mortality and morbidity. For the use of ECMO in the postcardiotomy cardiogenic shock (PCCS) population, retrospective studies and case series found some successful cases of weaning patients from ECMO in the setting of very high expected morbidity and mortality rates. However, without comparative studies, it is difficult to assess whether rates of weaning from bypass are better with ECMO than with standard care. When used for refractory cardiogenic shock, ECMO is accompanied by high mortality and complication rates. A propensity score-matched retrospective cohort study compared ECMO to Impella for patients with cardiogenic shock secondary to acute myocardial infarction and found higher rates of in-hospital mortality among patients treated with ECMO. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are adults in cardiac arrest who receive extracorporeal membrane oxygenation-assisted cardiopulmonary resuscitation (ECPR), the evidence includes 2 RCTs and a meta-analysis of comparative trials. Relevant outcomes are OS, change in disease status, morbid events, and treatment-related mortality and morbidity. The ARREST trial enrolled 30 patients and found a significant difference

in survival to discharge favoring early ECPR in the cardiac catheterization laboratory over standard advanced cardiac life support (ACLS) management in the emergency department. However, only 1 patient in the standard ACLS group survived to discharge, so further studies are required to examine comparative effects on long-term survival and functional outcomes. In the other RCT, a strategy of intra-arrest transport, ECPR and invasive assessment and treatment did not significantly improve survival with neurologically favorable outcomes at 180 days as compared to standard resuscitation. Multiple unanswered questions remain about the role of ECPR in refractory cardiac arrest, including appropriate patient populations, duration of conventional CPR, and assessment of futility. Studies have begun to address these questions, with results indicating that patients with an initial shockable cardiac rhythm, shorter low-flow duration, higher arterial pH, and lower serum lactate concentrations on hospital admission experienced favorable outcomes. Further study is needed to evaluate efficacy and define the population that may benefit from this treatment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
7/2023	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
6/2022	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
6/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
7/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
6/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
10/2018	Clarified coding information.
6/2018	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
6/2017	Annual policy review. New references added.
7/2016	Annual policy review. New references added.
6/2015	New medical policy describing medically necessary and investigational indications. Effective 6/1/2015.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Maslach-Hubbard A, Bratton SL. Extracorporeal membrane oxygenation for pediatric respiratory failure: History, development and current status. *World J Crit Care Med.* Nov 04 2013; 2(4): 29-39. PMID 24701414
2. Morris AH, Wallace CJ, Menlove RL, et al. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO₂ removal for adult respiratory distress syndrome. *Am J Respir Crit Care Med.* Feb 1994; 149(2 Pt 1): 295-305. PMID 8306022
3. Zapol WM, Snider MT, Hill JD, et al. Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. *JAMA.* Nov 16 1979; 242(20): 2193-6. PMID 490805
4. Combes A, Bacchetta M, Brodie D, et al. Extracorporeal membrane oxygenation for respiratory failure in adults. *Curr Opin Crit Care.* Feb 2012; 18(1): 99-104. PMID 22186218

5. Morimont P, Batchinsky A, Lambermont B. Update on the role of extracorporeal CO₂ removal as an adjunct to mechanical ventilation in ARDS. *Crit Care*. Mar 16 2015; 19(1): 117. PMID 25888428
6. U.S. Food and Drug Administration. Enforcement policy for extracorporeal membrane oxygenation and cardiopulmonary bypass devices during the coronavirus disease 2019 (COVID-19) public health emergency. Guidance for industry and Food and Drug Administration Staff. April 2020. <https://www.fda.gov/media/136734/download>. Accessed March 29, 2023.
7. U.S. Food and Drug Administration. Anesthesiology Devices; Reclassification of Membrane Lung for Long-Term Pulmonary Support; Redesignation as Extracorporeal Circuit and Accessories for Long-Term Respiratory/Cardiopulmonary Failure. 2016; <https://www.federalregister.gov/documents/2016/02/12/2016-02876/anesthesiology-devices-reclassification-of-membrane-lung-for-long-term-pulmonary-support>. Accessed March 28, 2023.
8. Tramm R, Ilic D, Davies AR, et al. Extracorporeal membrane oxygenation for critically ill adults. *Cochrane Database Syst Rev*. Jan 22 2015; 1(1): CD010381. PMID 25608845
9. Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet*. Oct 17 2009; 374(9698): 1351-63. PMID 19762075
10. Bein T, Weber-Carstens S, Goldmann A, et al. Lower tidal volume strategy (\approx 3 ml/kg) combined with extracorporeal CO₂ removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. *Intensive Care Med*. May 2013; 39(5): 847-56. PMID 23306584
11. Shrestha DB, Sedhai YR, Budhathoki P, et al. Extracorporeal Membrane Oxygenation (ECMO) Dependent Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis. *Cureus*. Jun 2022; 14(6): e25696. PMID 35812597
12. Combes A, Peek GJ, Hajage D, et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. *Intensive Care Med*. Nov 2020; 46(11): 2048-2057. PMID 33021684
13. Vaquer S, de Haro C, Peruga P, et al. Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome. *Ann Intensive Care*. Dec 2017; 7(1): 51. PMID 28500585
14. Zampieri FG, Mendes PV, Ranzani OT, et al. Extracorporeal membrane oxygenation for severe respiratory failure in adult patients: a systematic review and meta-analysis of current evidence. *J Crit Care*. Dec 2013; 28(6): 998-1005. PMID 23954453
15. Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). *JAMA*. Oct 19 2011; 306(15): 1659-68. PMID 21976615
16. Pham T, Combes A, Rozé H, et al. Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. *Am J Respir Crit Care Med*. Feb 01 2013; 187(3): 276-85. PMID 23155145
17. Zangrillo A, Biondi-Zoccai G, Landoni G, et al. Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO. *Crit Care*. Feb 13 2013; 17(1): R30. PMID 23406535
18. Combes A, Hajage D, Capellier G, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. *N Engl J Med*. May 24 2018; 378(21): 1965-1975. PMID 29791822
19. Shaefi S, Brenner SK, Gupta S, et al. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. *Intensive Care Med*. Feb 2021; 47(2): 208-221. PMID 33528595
20. Roch A, Lepaul-Ercole R, Grisoli D, et al. Extracorporeal membrane oxygenation for severe influenza A (H1N1) acute respiratory distress syndrome: a prospective observational comparative study. *Intensive Care Med*. Nov 2010; 36(11): 1899-905. PMID 20721530
21. Davies A, Jones D, Bailey M, et al. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. *JAMA*. Nov 04 2009; 302(17): 1888-95. PMID 19822628
22. Guirand DM, Okoye OT, Schmidt BS, et al. Venovenous extracorporeal life support improves survival in adult trauma patients with acute hypoxemic respiratory failure: a multicenter retrospective cohort study. *J Trauma Acute Care Surg*. May 2014; 76(5): 1275-81. PMID 24747460

23. Schechter MA, Ganapathi AM, Englum BR, et al. Spontaneously Breathing Extracorporeal Membrane Oxygenation Support Provides the Optimal Bridge to Lung Transplantation. *Transplantation*. Dec 2016; 100(12): 2699-2704. PMID 26910331
24. Hayes D, Higgins RS, Kilic A, et al. Extracorporeal membrane oxygenation and retransplantation in lung transplantation: an analysis of the UNOS registry. *Lung*. Aug 2014; 192(4): 571-6. PMID 24816903
25. Nosotti M, Rosso L, Tosi D, et al. Extracorporeal membrane oxygenation with spontaneous breathing as a bridge to lung transplantation. *Interact Cardiovasc Thorac Surg*. Jan 2013; 16(1): 55-9. PMID 23097371
26. Rehder KJ, Turner DA, Hartwig MG, et al. Active rehabilitation during extracorporeal membrane oxygenation as a bridge to lung transplantation. *Respir Care*. Aug 2013; 58(8): 1291-8. PMID 23232742
27. Inci I, Klinzing S, Schneider D, et al. Outcome of Extracorporeal Membrane Oxygenation as a Bridge To Lung Transplantation: An Institutional Experience and Literature Review. *Transplantation*. Aug 2015; 99(8): 1667-71. PMID 26308302
28. Hoopes CW, Kukreja J, Golden J, et al. Extracorporeal membrane oxygenation as a bridge to pulmonary transplantation. *J Thorac Cardiovasc Surg*. Mar 2013; 145(3): 862-7; discussion 867-8. PMID 23312979
29. Lafarge M, Mordant P, Thabut G, et al. Experience of extracorporeal membrane oxygenation as a bridge to lung transplantation in France. *J Heart Lung Transplant*. Sep 2013; 32(9): 905-13. PMID 23953818
30. Wang L, Wang H, Hou X. Clinical Outcomes of Adult Patients Who Receive Extracorporeal Membrane Oxygenation for Postcardiotomy Cardiogenic Shock: A Systematic Review and Meta-Analysis. *J Cardiothorac Vasc Anesth*. Oct 2018; 32(5): 2087-2093. PMID 29678433
31. Kowalewski M, Zieliński K, Brodie D, et al. Venoarterial Extracorporeal Membrane Oxygenation for Postcardiotomy Shock-Analysis of the Extracorporeal Life Support Organization Registry. *Crit Care Med*. Jul 01 2021; 49(7): 1107-1117. PMID 33729722
32. Biancari F, Perrotti A, Ruggieri VG, et al. Five-year survival after post-cardiotomy veno-arterial extracorporeal membrane oxygenation. *Eur Heart J Acute Cardiovasc Care*. Aug 24 2021; 10(6): 595-601. PMID 33580776
33. Rastan AJ, Dege A, Mohr M, et al. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. *J Thorac Cardiovasc Surg*. Feb 2010; 139(2): 302-11, 311.e1. PMID 20106393
34. Slottosch I, Liakopoulos O, Kuhn E, et al. Outcomes after peripheral extracorporeal membrane oxygenation therapy for postcardiotomy cardiogenic shock: a single-center experience. *J Surg Res*. May 2013; 181(2): e47-55. PMID 22878151
35. Bakhtiyar F, Keller H, Dogan S, et al. Venoarterial extracorporeal membrane oxygenation for treatment of cardiogenic shock: clinical experiences in 45 adult patients. *J Thorac Cardiovasc Surg*. Feb 2008; 135(2): 382-8. PMID 18242273
36. Xie A, Phan K, Tsai YC, et al. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest: a meta-analysis. *J Cardiothorac Vasc Anesth*. 2015; 29(3): 637-45. PMID 25543217
37. Lemor A, Hosseini Dehkordi SH, Basir MB, et al. Impella Versus Extracorporeal Membrane Oxygenation for Acute Myocardial Infarction Cardiogenic Shock. *Cardiovasc Revasc Med*. Dec 2020; 21(12): 1465-1471. PMID 32605901
38. Dobrilovic N, Lateef O, Michalak L, et al. Extracorporeal Membrane Oxygenation Bridges Inoperable Patients to Definitive Cardiac Operation. *ASAIO J*. Jan 2019; 65(1): 43-48. PMID 29240627
39. Aso S, Matsui H, Fushimi K, et al. In-hospital mortality and successful weaning from venoarterial extracorporeal membrane oxygenation: analysis of 5,263 patients using a national inpatient database in Japan. *Crit Care*. Apr 05 2016; 20: 80. PMID 27044572
40. Diddle JW, Almodovar MC, Rajagopal SK, et al. Extracorporeal membrane oxygenation for the support of adults with acute myocarditis. *Crit Care Med*. May 2015; 43(5): 1016-25. PMID 25738858
41. Lorusso R, Centofanti P, Gelsomino S, et al. Venoarterial Extracorporeal Membrane Oxygenation for Acute Fulminant Myocarditis in Adult Patients: A 5-Year Multi-Institutional Experience. *Ann Thorac Surg*. Mar 2016; 101(3): 919-26. PMID 26518372

42. El Sibai R, Bachir R, El Sayed M. ECMO use and mortality in adult patients with cardiogenic shock: a retrospective observational study in U.S. hospitals. *BMC Emerg Med.* Jul 04 2018; 18(1): 20. PMID 29973150
43. Scquizzato T, Bonaccorso A, Consonni M, et al. Extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest: A systematic review and meta-analysis of randomized and propensity score-matched studies. *Artif Organs.* May 2022; 46(5): 755-762. PMID 35199375
44. Yannopoulos D, Bartos J, Raveendran G, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. *Lancet.* Dec 05 2020; 396(10265): 1807-1816. PMID 33197396
45. Belohlavek J, Smalcova J, Rob D, et al. Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. *JAMA.* Feb 22 2022; 327(8): 737-747. PMID 35191923
46. Rob D, Smalcova J, Smid O, et al. Extracorporeal versus conventional cardiopulmonary resuscitation for refractory out-of-hospital cardiac arrest: a secondary analysis of the Prague OHCA trial. *Crit Care.* Oct 27 2022; 26(1): 330. PMID 36303227
47. Shin TG, Choi JH, Jo IJ, et al. Extracorporeal cardiopulmonary resuscitation in patients with in-hospital cardiac arrest: A comparison with conventional cardiopulmonary resuscitation. *Crit Care Med.* Jan 2011; 39(1): 1-7. PMID 21057309
48. Chen YS, Lin JW, Yu HY, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. *Lancet.* Aug 16 2008; 372(9638): 554-61. PMID 18603291
49. Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation.* Oct 20 2020; 142(16_suppl_2): S366-S468. PMID 33081529
50. ELSO Guideline for Adult Respiratory Failure Managed with Venovenous ECMO. Updated June 2021; <https://www.else.org/ecmo-resources/else-ecmo-guidelines.aspx>. Accessed April 3, 2023.
51. Richardson ASC, Tonna JE, Nanjaya V, et al. Extracorporeal Cardiopulmonary Resuscitation in Adults. Interim Guideline Consensus Statement From the Extracorporeal Life Support Organization. *ASAIO J.* Mar 01 2021; 67(3): 221-228. PMID 33627592
52. Lorusso R, Whitman G, Milojevic M, et al. 2020 EACTS/ELSO/STS/AATS expert consensus on post-cardiotomy extracorporeal life support in adult patients. *J Thorac Cardiovasc Surg.* Apr 2021; 161(4): 1287-1331. PMID 33039139
53. Badulak J, Antonini MV, Stead CM, et al. Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization. *ASAIO J.* May 01 2021; 67(5): 485-495. PMID 33657573
54. Combes A, Brodie D, Bartlett R, et al. Position paper for the organization of extracorporeal membrane oxygenation programs for acute respiratory failure in adult patients. *Am J Respir Crit Care Med.* Sep 01 2014; 190(5): 488-96. PMID 25062496
55. Abrams D, Garan AR, Abdelbary A, et al. Position paper for the organization of ECMO programs for cardiac failure in adults. *Intensive Care Med.* Jun 2018; 44(6): 717-729. PMID 29450594
56. National Institute for Health and Care Excellence (NICE). Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults [IPG482]. 2014; <https://www.nice.org.uk/Guidance/ipg482>. Accessed April 3, 2023.
57. National Institute for Health and Care Excellence (NICE). Extracorporeal membrane oxygenation for severe acute respiratory failure in adults [IPG391]. 2011; <https://www.nice.org.uk/guidance/IPG391/chapter/1-guidance>. Accessed April 1, 2023.